home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2796.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
52 lines
Document 2796
DOCN M94A2796
TI The role of hrGM-CSF in neutropenia due to the cytostatic or ganciclovir
treatment.
DT 9412
AU Szlavik J; Banhegyl D; Miskovits E; Gerlei Z; Saint Laszlo Hospital,
Department of Immunology, Budapest,; Hungary.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):222 (abstract no. PB0316). Unique
Identifier : AIDSLINE ICA10/94369779
AB OBJECTIVE: Identification of the role of human recombinant
granulocyte-monocyte stimulating factor in neutropenia due to cytostatic
treatment of Kaposi's sarcoma and non-Hodgkin's lymphoma associated with
AIDS and that of the effectivity of hrGM-CSF in neutropenia due to
ganciclovir treatment of cytomegalovirus retinitis. METHODS:
Subcutaneous hrGM-CSF therapy (5 ug/kg/day) was applied for 7-17 days,
after BACOD therapy in neutropenia of three patients with B-cell
non-Hodgkin's lymphoma, while cytokine therapy in the same dose was
applied in neutropenia of two patients with Kaposi's sarcoma due to BVA
therapy. We tried to treat neutropenia due to inductive application of
ganciclovir with a dose of 3-5 ug/kg/day of hrGM-CSF in eight patients
with CMV retinitis. RESULTS: 13 patients (mean age: 32 years) were given
3-5 ug/kg/day sc. hrGM-CSF for 7-17 days (mean: 9.5). The initial
neutrophil count 0.3-1.4 x 10(9)/l (mean: 0.7) increased to 1.8-9.3 x
10(9)/l (mean: 4.2) in the patients with KS and NHL as a result of
treatment (mean CD4+: 102/mm3). There was a more significant increase in
the neutrophil count in neutropenia due to ganciclovir treatment
resulted by seven days treatment from the initial 0.8-2.1 x 10(9)/l
(mean: 1.1) to 3.6-15.8 x 10(9)/l (mean: 4.2), (mean CD4+: 173/mm3). In
the investigation period there was no infection observed in association
with neutropenia, the main adverse effects of hrGM-CSF were fever in 7,
fatigue and myalgia in 5 and confusion in 1 case. DISCUSSION: Cytokine
therapy applied in combination is effective in neutropenia due to both
the cytostatic treatment of tumours and ganciclovir treatment,
infections associated with neutropenia can be prevented by it, although
the effect depends on the initial CD4+ lymphocyte count of the patient.
DE Adult Antineoplastic Agents, Combined/*ADVERSE EFFECTS/THERAPEUTIC USE
Biological Response Modifiers/*THERAPEUTIC USE
Bleomycins/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
Cytomegalovirus Retinitis/DRUG THERAPY Dexamethasone/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS Doxorubicin/ADMINISTRATION & DOSAGE/ADVERSE
EFFECTS Ganciclovir/*ADVERSE EFFECTS Granulocyte-Macrophage
Colony-Stimulating Factor/*THERAPEUTIC USE Human HIV
Infections/COMPLICATIONS Lymphoma, AIDS-Related/DRUG THERAPY
Neutropenia/CHEMICALLY INDUCED/*THERAPY Recombinant
Proteins/THERAPEUTIC USE Sarcoma, Kaposi's/DRUG THERAPY
Vincristine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).